Interruption of HBV intrauterine transmission： A clinical study

• Published in: World journal of gastroenterology : WJG 2003-07, Vol.9 (7), p.1501-1503
• Main Authors: Li, Xiao-Mao, Yang, Yue-Bo, Hou, Hong-Ying, Shi, Zhong-Jie, Shen, Hui-Min, Teng, Ben-Qi, Li, Ai-Min, Shi, Min-Feng, Zou, Ling
• Format: Article
• Language: English
• Subjects: Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; DNA, Viral - analysis; Female; Hepatitis B - drug therapy; Hepatitis B - epidemiology; Hepatitis B - prevention & control; Hepatitis B - transmission; Hepatitis B e Antigens - genetics; Hepatitis B Surface Antigens - genetics; Humans; Immunoglobulins - administration & dosage; Immunoglobulins - adverse effects; Incidence; Infant, Newborn; Infectious Disease Transmission, Vertical - prevention & control; Lamivudine - administration & dosage; Lamivudine - adverse effects; Pregnancy; Viral Hepatitis; 乙型肝炎; 乙型肝炎免疫球蛋白; 宫内传播; 拉米夫定
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v9.i7.1501

AIM: To investigate the effect of hepatitis B virus (HBV) specific immunoglobin (HBIG) and lamivudine on HBV intrauterine transmission in HBsAg positive pregnant women. METHODS: Each subject in the HBIG group (56 cases) was given 200 IU HBIG intramuscularly (im.) every 4 weeks from 28-week (wk) of gestation, while each subject in the lamivudine group (43 cases) received 100 mg lamivudine orally (po.) even/day from 28-wk of gestation until the 30^th day after labor. Subjects in the control group (52 cases) received no specific treatment. Blood specimens were tested for HBsAg, HBeAg, and HBV-DNA in all maternities at 28-wk of gestation, before delivery, and in their newborns 24 hours before the administration of immune prophylaxis.RESULTS: Reductions of HBV DNA in both treatments were significant (P